VedaBio

VedaBio discovered genuine demand for rapid syndromic testing when clinicians began requesting their CRISPR-powered diagnostic platform unprompted during beta trials. Rather than relying on survey responses about interest in faster results, the team measured actual behavior: emergency departments and urgent care centers started restructuring workflows around the device's five-minute turnaround time, indicating they valued speed enough to change operations. Early traction emerged through repeat orders from pilot sites, with physicians ordering tests at higher volumes than predicted, suggesting real clinical need rather than polite interest. The strongest validation came when hospitals began integrating VedaBio's results into treatment protocols immediately—doctors weren't just running tests but actively using comprehensive syndromic data to guide patient care decisions within minutes. This behavioral shift from traditional hour-long diagnostics to minute-level decision-making proved demand existed beyond stated preferences. Clinicians' willingness to reorganize their diagnostic workflows and treatment timelines demonstrated they recognized genuine value in eliminating the diagnostic bottleneck that had constrained their practice for years.